News | PET-MRI | December 10, 2020

Post-neoadjuvant therapy changes in metabolic metrics from PET/MRI and morphologic metrics from CT were associated with pathologic response and overall survival in patients with pancreatic ductal adenocarcinoma

Post-neoadjuvant therapy changes in metabolic metrics from PET/MRI and morphologic metrics from CT were associated with pathologic response and overall survival in patients with pancreatic ductal adenocarcinoma

Pre-treatment (A-C) and post-treatment (D-F) images after eight cycles of systemic FOLFIRINOX and consolidative chemoradiation. Baseline CA 19-9 was 145 U/ml. Pre-treatment whole body axial fused PET/MRI showed FDG avid lesion in body of pancreas (arrow, A) with SUVmax 7.1 and SUVgluc 8.0. Lesion was hypo-enhancing on axial contrast-enhanced T1-weighted (T1W) MR image (arrow, B) from focused abdominal PET/MRI and on CT (arrow, C). Pre-treatment CT tumor volume was 10.3 cm3. Post-treatment whole body axial fused PET/MRI showed complete metabolic response (arrow D) with SUVmax 1.9 and SUVgluc 1.9. Lesion was indistinct on axial contrast-enhanced T1W MRI (arrow, E) and CT (arrow, F), and there was upstream pancreatic parenchymal atrophy. Post-treatment CT tumor volume was 0.46 cm3. There was normalization of CA 19-9. Relative change in SUVmax (ΔSUVgluc) was -73%, and relative change in SUVgluc (ΔSUVgluc) was -76%. Based on change in tumor size, response was categorized as partial response per RECIST. Relative change in tumor volume (ΔTvol) was -96%. Pathology showed major pathologic response (College of American Pathologists score 1.) Images courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)


December 10, 2020 — According to an open-access Editor's Choice article in ARRS' American Journal of Roentgenology (AJR), post-neoadjuvant therapy (NAT) changes in metabolic metrics from PET/MRI and morphologic metrics from CT were associated with pathologic response and overall survival in patients with pancreatic ductal adenocarcinoma (PDA).

"Imaging metrics associated with pathologic response and overall survival in PDA could help guide clinical management and outcomes for patients with PDA receiving emergent therapeutic interventions," wrote first author Ananya Panda of the department of radiology at the Mayo Clinic in Rochester, Minnesota.

Panda and colleagues' retrospective study included 44 patients (22 men, 22 women; average age 62) with 18F-FDG avid borderline resectable or locally advanced PDA on pre-treatment PET/MRI, who also underwent post-NAT PET/MRI prior to surgery between August 2016 and September 2019. CA 19-9, metabolic metrics from PET/MRI, and morphologic metrics from CT (n = 34) were compared between pathologic responders (College of American Pathologists scores 0 and 1] and nonresponders (scores 2 and 3).

In borderline resectable or locally advanced pancreatic cancer undergoing neoadjuvant therapy, pre- vs. post-treatment changes in tumor metrics on PET/MRI (complete metabolic response, ΔSUVmax, ΔSUVgluc) and CT (RECIST, volume change) were associated with major pathologic response (AUC = 0.71-0.83; p < 0.05).

Reiterating that PET/MRI and CT metrics can help guide post-NAT pancreatic cancer treatment decisions, the authors of this AJR article concluded that by comparison, serum CA 19-9 was not associated with pathologic response or survival.

For more information: www.arrs.org


Related Content

News | Artificial Intelligence

March 17, 2023 — A new paper published in the Journal of Medical Internet Research describes how generative models such ...

Time March 17, 2023
arrow
News | Quality Assurance (QA)

March 16, 2023 — RTsafe, a leading provider of quality assurance products and services in stereotactic radiosurgery ...

Time March 16, 2023
arrow
News | Lung Imaging

March 15, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Time March 15, 2023
arrow
News | Radiation Oncology

March 14, 2023 — Elekta announced that is has signed a joint venture with China National Pharmaceutical Group Co., Ltd. ...

Time March 14, 2023
arrow
News | Digital Pathology

March 13, 2023 — Proscia, a leading provider of digital and computational pathology solutions, today announced that ...

Time March 13, 2023
arrow
News | Artificial Intelligence

March 10, 2023 — Computed tomography (CT) is one of the most powerful and well-established diagnostic tools available to ...

Time March 10, 2023
arrow
News | Coronavirus (COVID-19)

March 10, 2023 — Researchers found evidence of heart muscle inflammation in a small number of patients with acute ...

Time March 10, 2023
arrow
Feature | Radiology Business | By Christine Book

With an increasing focus on personalizing the patient experience and enhancing communication between radiologists and ...

Time March 10, 2023
arrow
News | Digital Pathology

March 7, 2023 — Proscia, a leading provider of digital and computational pathology solutions, today announced that ...

Time March 07, 2023
arrow
News | ARRS

March 6, 2023 — The American Roentgen Ray Society (ARRS) proudly recognizes the following four radiologists, as well as ...

Time March 06, 2023
arrow
Subscribe Now